Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL729439 | 0.86 | ADORA3 (0.40) | ADORA3ADORA1MEN1ALDH1A1HPGD | |
| SCHEMBL728568 | 0.78 | ADORA3 (0.47) | ADORA3ADORA1MEN1ALDH1A1HPGD | |
| SCHEMBL730469 | 0.76 | ADORA3 (0.53) | ADORA3ADORA1HPGD | |
| SCHEMBL728854 | 0.76 | ADORA3 (0.45) | ADORA3ADORA1ALDH1A1 | |
| SCHEMBL726536 | 0.76 | ALDH1A1 (0.47) | ADORA3ADORA1MEN1ALDH1A1HPGD | |
| SCHEMBL728613 | 0.76 | ADORA3 (0.47) | ADORA3ADORA1ALDH1A1 | |
| SCHEMBL5512657 | 0.75 | CHEK1 (0.46) | ADORA3MEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL729014 | 0.75 | UTS2R (0.39) | ADORA3ALDH1A1HPGDPOLB | |
| SCHEMBL735233 | 0.74 | KDM4E (0.51) | ADORA3TP53ALDH1A1HPGD | |
| SCHEMBL728571 | 0.74 | KHK (0.38) | ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138173-B2 | Pyrazolo[3,4-C]quinolines, pyrazolo[3,4-C]naphthyridines, analogs thereof, and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-03-20 | — | — | US | disclosed |